Lennox-Gastaut Syndrome (LGS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Lennox-Gastaut Syndrome (LGS) Marketed and Pipeline Drugs Report Overview
Lennox-Gastaut Syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. Affected children experience several different types of seizures, such as atonic, tonic, and atypical absence seizures. Children with LGS may also develop cognitive dysfunction, delays in reaching developmental milestones, and behavioral problems.
| Key Mechanism of Action (Marketed) | · Receptor Agonists
· Ion Channel Blockers · Enzyme Inhibitors · Receptor Antagonists · Transporter Inhibitors · Ion Channel Inhibitors |
| Key Routes of Administration (Marketed) | · Injection
· Oral · Topical · Suppository |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Lennox-Gastaut Syndrome (LGS) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, and late-to-mid-stage pipeline products with Phase transition success rate (PTSR) and the likelihood of approval (LoA) for Lennox-Gastaut Syndrome (LGS). The report also analyzes the clinical and commercial landscapes of LGS, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
| Key Mechanisms of Action (Pipeline) | · Receptor Agonists
· Ion Channel Blockers · Receptor Antagonists · Enzyme Inhibitors · Receptor Modulators · Transporter Inhibitors · Ion Channel Inhibitors |
| Key Routes of Administration (Pipeline) | · Injection
· Oral · Topical |
| Key Molecule Types (Pipeline) | · Biologics
· Small Molecules |
| Top Sponsors (Marketed and Pipeline Drugs) | · Takeda Pharmaceutical Co Ltd
· GW Pharmaceuticals Ltd · Zogenix Inc · SK Life Science Inc · Marinus Pharmaceuticals Inc |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
LGS Marketed Drugs Segmentation by Mechanisms of Action
Most of the marketed drugs for Lennox-Gastaut Syndrome are receptor agonists by the mechanism of action, followed by ion channel blockers, enzyme inhibitors, receptor antagonists, transporter inhibitors, and ion channel inhibitors.
LGS Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of LGS Marketed Drugs
LGS Marketed Drugs Segmentation by Routes of Administration
Most of the LGS-marketed drugs are orally administered, followed by injectable, topical, and suppository.
LGS Marketed Drugs Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of LGS Marketed Drugs
LGS Pipeline Drugs Market Segmentation by Mechanisms of Action
Most of the pipeline drugs in the Lennox-Gastaut Syndrome landscape are receptor agonists, followed by ion channel blockers and receptor antagonists in terms of mechanism of action. The other MoAs are enzyme inhibitors, receptor modulators, transporter inhibitors, and ion channel inhibitors.
LGS Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy Full Report to Know More about the MoA of LGS Pipeline Drugs
LGS Pipeline Drugs Market Segmentation by Routes of Administration
Most pipeline drugs for LGS are oral drugs, followed by injectable therapies and topical drugs.
LGS Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy Full Report to Know More about the RoA of LGS Pipeline Drugs
LGS Pipeline Drugs Market Segmentation by Molecule Types
Most pipeline drugs for Lennox-Gastaut Syndrome are small molecules, followed by biologics.
LGS Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of LGS Pipeline Drugs
LGS Marketed and Pipeline Drugs Market – Competitive Landscape
Some of the top sponsors in the LGS marketed and pipeline drugs market are Takeda Pharmaceutical Co Ltd, GW Pharmaceuticals Ltd, Zogenix Inc, SK Life Science Inc, and Marinus Pharmaceuticals Inc. In 2023, Takeda Pharmaceutical Co Ltd leads among the trial sponsors after adding up all the trial phases. Commercial sponsors have led the clinical trials space for LGS over the past 10 years.
LGS Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy Full Report for More Sponsor Insights into the LGS Marketed and Pipeline Drugs Market Download A Free Report Sample
Segments Covered in the Report
LGS Marketed Drugs Mechanism of Action (Number of Drugs, 2023)
- Receptor Agonists
- Ion Channel Blockers
- Enzyme Inhibitors
- Receptor Antagonists
- Transporter Inhibitors
- Ion Channel Inhibitors
LGS Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Topical
- Suppository
LGS Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Agonists
- Ion Channel Blockers
- Receptor Antagonists
- Enzyme Inhibitors
- Receptor Modulators
- Transporter Inhibitors
- Ion Channel Inhibitors
LGS Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Topical
LGS Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologics
- Small Molecules
Scope
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the LGS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global LGS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which is the leading MoA for LGS marketed drugs?
In 2023, most of the marketed drugs for LGS are receptor agonists.
-
Which is the leading RoA for LGS marketed drugs?
In 2023, most of the marketed drugs for LGS are administered orally.
-
Which is the leading MoA for LGS pipeline drugs?
In 2023, most of the LGS pipeline drugs are receptor agonists.
-
Which is the leading RoA for LGS pipeline drugs?
In 2023, most of the drugs in the LGS pipeline are administered orally.
-
Which is the leading molecule type for LGS pipeline drugs?
In 2023, most of the pipeline drugs for LGS are small molecules.
-
Who are the top sponsors for LGS marketed and pipeline drugs market?
Some of the top sponsors in the LGS marketed and pipeline drugs market are Takeda Pharmaceutical Co Ltd, GW Pharmaceuticals Ltd, Zogenix Inc, SK Life Science Inc, and Marinus Pharmaceuticals Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Lennox-Gastaut Syndrome (LGS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Lennox-Gastaut Syndrome reports